Spruce Biosciences GAAP EPS of -0.21 beats by 0.04

LSTA Stock  USD 2.65  0.07  2.71%   
About 55% of Lisata Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Lisata Therapeutics suggests that some traders are interested. The current market sentiment, together with Lisata Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lisata Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Spruce Biosciences reports Q3 GAAP EPS of -0.21, beating by 0.04.

Read at seekingalpha.com
seekingalpha News
  

Lisata Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Lisata Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Lisata Therapeutics Fundamental Analysis

We analyze Lisata Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lisata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lisata Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Probability Of Bankruptcy

Probability Of Bankruptcy Comparative Analysis

Lisata Therapeutics is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.

Lisata Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lisata Therapeutics stock to make a market-neutral strategy. Peer analysis of Lisata Therapeutics could also be used in its relative valuation, which is a method of valuing Lisata Therapeutics by comparing valuation metrics with similar companies.

Peers

Lisata Therapeutics Related Equities

LIXTLixte Biotechnology   19.60   
0%
100.0%
PTIXProtagenic Therapeutics   7.69   
0%
39.0%
PULMPulmatrix   7.30   
0%
37.0%
CADLCandel Therapeutics   6.82   
0%
34.0%
BPTHBio Path   3.58   
0%
18.0%
IMNNImunon   3.57   
0%
18.0%
GLUEMonte Rosa   1.46   
0%
7.0%
XOMAOXOMA   0.12   
0%
1.0%
RZLTRezolute   1.11   
5.0%
0%
TPSTTempest Therapeutics   1.25   
6.0%
0%
ANTXAN2 Therapeutics   6.29   
32.0%
0%
MBRXMoleculin Biotech   15.07   
76.0%
0%

Complementary Tools for Lisata Stock analysis

When running Lisata Therapeutics' price analysis, check to measure Lisata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lisata Therapeutics is operating at the current time. Most of Lisata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Lisata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lisata Therapeutics' price. Additionally, you may evaluate how the addition of Lisata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm